Atai advances oral psychedelic in depression

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning, the FDA’s recent rejection of an MDMA therapy hasn’t seemed to deter some other companies from moving ahead with psychedelics studies. We discuss that, and also some big policy developments that are coming this week.

Atai advances oral psychedelic in depression

From STAT’s Meghana Keshavan: The FDA may have recently rejected MDMA-assisted psychotherapy, but other players in the psychedelics space are moving ahead with candidates. Atai Life Sciences this morning reported early data from its Phase 1b trial testing an oral form of the psychedelic DMT for treatment-resistant depression.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In